Sanofi and Regeneron's asthma drug Dupixent succeeded in a study of patients with "smoker's lung," leading SNY and REGN stocks to rocket. The post Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung' appeared first on Investor's Business Daily.
Full Story >>
Vote
+3